3.85

7.67% -0.32

After Hours: 3.81 -0.04 -1.04%

C 4 Therapeutics Inc (CCCC)

Overview News Price History Option Chain Financials Discussions Forecast

C 4 Therapeutics Inc stock is traded at $3.85, with a volume of 2.13M. It is down -7.67% in the last 24 hours and up +29.63% over the past month. C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

Previous Close:

$4.17

Open:

$4.15

24h Volume:

2.13M

Relative Volume:

0.75

Market Cap:

$425.68M

Revenue:

$35.95M

Net Income/Loss:

$-104.99M

P/E Ratio:

-2.8378

EPS:

-1.3567

Net Cash Flow:

$-99.30M

1W Performance:

-11.90%

1M Performance:

+29.63%

6M Performance:

+44.19%

1Y Performance:

+161.90%

1-Day Range:

$3.785

$4.16

1-Week Range:

$3.785

$4.5981

52-Week Range:

$1.36

$4.5981

C 4 Therapeutics Inc Stock (CCCC) Company Profile

Name

C 4 Therapeutics Inc

Sector

Healthcare (1102)

Industry

Biotechnology (614)

Phone

(617) 231-0700

Address

490 ARSENAL WAY, WATERTOWN

Employee

104

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

CCCC's Discussions on Twitter

Compare CCCC vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CCCC C 4 Therapeutics Inc	3.85	461.07M	35.95M	-104.99M	-99.30M	-1.3567
VRTX Vertex Pharmaceuticals Inc	446.83	112.12B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	635.45	65.92B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	891.32	52.38B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.05	40.54B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	149.23	33.10B	742.00K	-1.37B	-1.07B	-7.0731

C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-02-25	Initiated	TD Cowen	Buy
Sep-17-25	Initiated	Barclays	Overweight
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight
Sep-04-25	Initiated	Guggenheim	Buy
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Nov-18-24	Initiated	Stephens	Equal-Weight
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral
Dec-13-23	Upgrade	Stifel	Hold → Buy
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral
Oct-11-22	Initiated	Morgan Stanley	Underweight
Apr-28-22	Initiated	Credit Suisse	Underperform
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral
Mar-10-22	Initiated	JP Morgan	Overweight
Feb-11-22	Resumed	BMO Capital Markets	Outperform
Feb-10-22	Initiated	Wells Fargo	Equal Weight
Nov-23-21	Initiated	BofA Securities	Buy
Oct-14-21	Initiated	SVB Leerink	Mkt Perform
Sep-30-21	Initiated	Stifel	Hold
Jun-04-21	Initiated	H.C. Wainwright	Buy
Mar-31-21	Initiated	BMO Capital Markets	Outperform
Oct-28-20	Initiated	UBS	Buy
Oct-27-20	Initiated	BMO Capital Markets	Outperform
Oct-27-20	Initiated	Jefferies	Buy

View All

C 4 Therapeutics Inc Stock (CCCC) Latest News

05:02 AM

Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record

05:02 AM

04:37 AM

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

04:37 AM

04:05 AM

New Intellia hires receive 47,150 RSUs in Nasdaq inducement plan - Stock Titan

04:05 AM

07:00 AM

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - FinancialContent

07:00 AM

Jun 04, 2026

Director Anderson (NASDAQ: CCCC) exercises 1,070 options at $2.11 - Stock Titan

Jun 04, 2026

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 04, 2026

Abeona Therapeutics (ABEO) details FDA Pre-IND meeting and 2027 IND goal for ABO-701 - Stock Titan

Jun 04, 2026

Jun 03, 2026

Viking Therapeutics (NASDAQ: VKTX) CMO awarded 190,000 stock options - Stock Titan

Jun 03, 2026

Viking Therapeutics (NASDAQ: VKTX) Chief Medical Officer named insider in Form 3 filing - Stock Titan

Jun 03, 2026

Executive team at C4 Therapeutics, Inc. set for Jefferies conference fireside chat - Traders Union

Jun 03, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jun 03, 2026

New Edgewise hires get 74,000 stock options as hiring inducement - Stock Titan

Jun 03, 2026